Livedoid vasculopathy; favorable clinical response with low dose warfarin

2011 ◽  
Vol 21 (6) ◽  
pp. 1011-1012 ◽  
Author(s):  
Satoshi Nakamura ◽  
Mari Kishibe ◽  
Kaoru Nishi ◽  
Yoshio Hashimoto ◽  
Keiko Takeda ◽  
...  
Keyword(s):  
Clinical Response ◽  
Low Dose ◽  
Dose Warfarin ◽  
Livedoid Vasculopathy ◽  
Favorable Clinical Response

Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis

2011 ◽  
Vol 23 (2) ◽  
pp. 112-115 ◽  
Author(s):  
Satoshi Nakamura ◽  
Keiko Takeda ◽  
Yoshio Hashimoto ◽  
Kaoru Nishi ◽  
Hidetoshi Takahashi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Response ◽  
Low Dose ◽  
Favorable Clinical Response

scholarly journals POS0407 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGIC-DMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 433.1-433
Author(s):  
T. Sornasse ◽  
J. Anderson ◽  
K. Kato ◽  
A. Lertratanakul ◽  
I. McInnes ◽  
...  
Keyword(s):  
Disease Activity ◽  
Clinical Response ◽  
Rheumatic Diseases ◽  
Inadequate Response ◽  
Protein Biomarkers ◽  
Research Support ◽  
Positive Correlation ◽  
Disease Biology ◽  
Biologic Dmard ◽  
Favorable Clinical Response

Background:Treatment of non-biologic-DMARD-IR1 (DMARD-IR) and biologic-DMARD-IR2 (bio-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in significant improvement in signs and symptoms compared to placebo.Objectives:Using a pre-defined set of inflammation-related plasma protein biomarkers (pBM), to explore immunological pathway modulation by UPA 15 mg QD in PsA patients with active disease despite treatment with non-biologic or biologic DMARDs in the context of clinical response vs. non-response to treatment.Methods:Patients from the SELECT-PsA 1 (DMARD-IR) and the SELECT-PsA 2 (bio-IR) studies were randomly selected (PBO, n=100; UPA 15 mg QD, n=100 for each study). The levels of 92 inflammation related protein biomarkers (pBM) were analyzed using a multiplexed Proximity Extension Assay platform in plasma samples collected at baseline, week 2, and 12; change from baseline in protein levels was expressed as Log2 Fold Change; a Repeated Measure Mixed Linear Model was used to identify pBM modulated by UPA compared to Baseline, and those differentially modulated between responders (R) and non-responders (NR) according to ACR50, PASDAS Minimal Disease Activity, and PASI75 at week 12. Correlation of disease activity measures with relative levels of pBM were derived using Pearson’s correlation; PASI score was transformed as Log10 (x+1) prior to the analysis. Functional pathway prediction was performed in silico with a commercial distributed software.Results:At baseline, the relative levels of 37 pBM correlated with at least one baseline disease activity measure, with a marked positive correlation of IL6 with musculoskeletal end points (PASDAS and DAS28CRP), and a strong positive correlation of IL20, IL17A, IL17C, and TGFA with baseline PASI.At the single pBM-level, treatment with UPA 15 mg QD resulted in a down modulation of pBM associated with T cells, myeloid cells, and IFN-, IL6-, and TNF-related pathways in both DMARD-IR and bio-IR PsA patients. Overall effects of UPA on single pBMs were broadly similar between DMARD-IR and bio-IR patients. However, analysis of pBMs differentially modulated by UPA in R vs NR indicated that favorable clinical response (achievement of ACR50, PASDAS MDA, and PASI75) in DMARD-IR patients was associated with the down modulation of pBMs predicted to be linked to IFN, IL10, IL17, IL22, and IL27 pathways; while favorable clinical response in bio-IR patients was associated with the down modulation of multiple pBM predicted to be linked to the IL17, IL23, and IL1 pathways.Conclusion:UPA effects in both DMARD-IR and bio-IR PsA patients likely stem from the direct and indirect inhibition of multiple biological pathways belonging to the adaptive and innate immune systems. Responder/Non-Responder analysis suggests a possible shift from a TH1 biased biology in DMARD-IR PsA patients to a more TH17 biased biology in bio-IR PsA patients. This apparent change in the disease biology of PsA patients after inadequate response to prior therapy could be attributed to the actual alteration of the disease biology, treatment outcome-based patient selection, or both. Considering the clinical efficacy of UPA in both DMARD-IR and bio-IR PsA patients, this observation highlights the importance of targeting multiple pathways with drugs such as UPA for the treatment of a broad range of PsA patients.References:[1]McInnes, I. et al. Annals of the Rheumatic Diseases 79, 16-17 (2020).[2]Mease, P.J. et al.Annals of the Rheumatic Diseases, annrheumdis-2020-218870 (2020).Acknowledgements:AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.Disclosure of Interests:Thierry Sornasse Shareholder of: AbbVie, Employee of: AbbVie, Jaclyn Anderson Shareholder of: AbbVie, Employee of: AbbVie, Koji Kato Shareholder of: AbbVie, Employee of: AbbVie, Apinya Lertratanakul Shareholder of: AbbVie, Employee of: AbbVie, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Pharma, Grant/research support from: AbbVie, Amgen, UCB

scholarly journals Field evaluation of low-dose warfarin baits to control wild pigs (Sus scrofa) in North Texas

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0206070 ◽  
Author(s):  
Richard M. Poché ◽  
David Poché ◽  
Greg Franckowiak ◽  
Daniel J. Somers ◽  
Lindsay N. Briley ◽  
...  
Keyword(s):  
Sus Scrofa ◽  
Low Dose ◽  
Field Evaluation ◽  
North Texas ◽  
Wild Pigs ◽  
Dose Warfarin

scholarly journals Dipyridamole and low-dose warfarin without cyclophosphamide in the management of IgA nephropathy

2000 ◽  
Vol 57 (1) ◽  
pp. 348-349 ◽  
Author(s):  
K.T. Woo ◽  
G.S.L. Lee ◽  
Abeed A. Pall
Keyword(s):  
Iga Nephropathy ◽  
Low Dose ◽  
Dose Warfarin
Sign in / Sign up

Export Citation Format

Share Document